Loading…
Myriad Genetics Inc
Myriad Genetics Inc (MYGN) is listed on NASDAQ and classified in Diagnostics & Research, part of the Healthcare sector. It is headquartered in Salt Lake City, United States and has 2,700 employees. The company is worth $550.94M. Revenue was $824.5M in fiscal 2025, down 1.6% from the year before. It reported a net loss of $365.9M. The share price is 32.2% below its 52-week high of $8.50. 5 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Israel Englander (Millennium Management), at $37.8M. In that quarter, 3 of them opened or added to the position and 1 reduced it. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
▼ -84.6% over 5Y.
today you would have $129.35▼ -87.1%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 17 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $6.15 | $13.71 | $19.14 | $14.51 | $27.60 | $19.77 | $27.23 | $29.07 | $34.35 | $16.67 | $43.16 | $34.06 | $20.98 | $27.25 | $20.94 | $22.84 | $26.09 | |
| P/E |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| FLGTFulgent Genetics, Inc. | $19.99 | — | 0.5x | 0.00% | -8.11% | $550.03M |
| ETRAElectra Therapeutics, Inc. | $8.75 | — | — | 0.00% | — | $549.21M |
| EVHEvolent Health, Inc. | $4.89 | — | 1.4x | 0.00% | -66.97% | $552.86M |
| STTKShattuck Labs, Inc. | $5.42 |
| 17.4x |
| — |
| — |
| — |
| — |
| — |
| — |
| 453.8x |
| 15.7x |
| 137.4x |
| 10.4x |
| 40.3x |
| 15.1x |
| 11.9x |
| 21.0x |
| 19.0x |
| 14.8x |
| 30.3x |
| P/S | 2.8x | 0.7x | 1.5x | 2.3x | 1.7x | 3.2x | 2.7x | 2.4x | 2.8x | 3.0x | 1.5x | 4.1x | 3.2x | 2.8x | 4.5x | 4.4x | 5.9x | 7.9x |
| P/B | 2.3x | 1.6x | 1.8x | 2.2x | 1.3x | 2.3x | 1.7x | 1.8x | 2.1x | 3.1x | 1.6x | 4.5x | 3.4x | 2.3x | 3.5x | 3.1x | 3.9x | 5.9x |
| EPS | -$3.95 | -$1.41 | -$3.18 | -$1.39 | -$0.35 | -$2.99 | $0.06 | $1.85 | $0.25 | $1.60 | $1.07 | $2.25 | $1.77 | $1.30 | $1.10 | $1.54 | $0.86 |
| Dividend yield | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 13.42% |
| Payout | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 406.98% |
| Profit margin | 11.04% | -44.38% | -15.20% | -34.96% | -16.51% | -3.94% | -40.14% | 0.54% | 17.92% | 2.26% | 15.55% | 11.04% | 22.64% | 24.01% | 22.61% | 25.05% | 42.00% | 25.91% |
| ROE | 12.06% | -99.43% | -18.16% | -33.62% | -12.64% | -2.81% | -25.38% | 0.42% | 13.80% | 2.26% | 15.85% | 12.06% | 24.51% | 20.20% | 17.64% | 17.77% | 27.31% | 19.49% |
Median of the years shown; P/E years above 200x are left out.
| — |
| 2.6x |
| 0.00% |
| -39.21% |
| $543.97M |
| GMRSGMR Solutions Inc. | $10.00 | — | 1.0x | 0.00% | — | $540.22M |
| SLNSilence Therapeutics plc | $8.68 | — | 10.7x | 0.00% | -90.41% | $539.5M |